Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is a slow-growing blood cancer that requires a careful, personalized approach to treatment. Depending on where it develops and what causes it, doctors may use strategies ranging from antibiotics to radiation, chemotherapy, or newer targeted drugs being tested in clinical trials.

Understanding Treatment Goals for MALT Lymphoma

When someone is diagnosed with extranodal marginal zone B-cell lymphoma, also called MALT lymphoma, the main goal of treatment is to control the disease, reduce symptoms, and improve quality of life. Because MALT lymphoma is typically slow-growing, treatment is not always urgent. In fact, many people diagnosed with this condition don’t have symptoms right away, and doctors may recommend careful monitoring rather than immediate treatment.^[1][3]

The treatment plan depends heavily on where the lymphoma is located in the body and what stage it has reached. MALT lymphoma can develop in many different organs, including the stomach, lungs, eyes, salivary glands, thyroid, skin, and other tissues. The most common site is the stomach, where the disease is often linked to a bacterial infection. Because of this connection, the first step in treating gastric MALT lymphoma may be as simple as treating the infection with antibiotics.^[4][8]

Treatment decisions also depend on the patient’s overall health, age, and whether the lymphoma is causing problems. For patients with early-stage disease that stays in one area, local treatments like radiation therapy or even surgery may be enough. For those with more advanced disease that has spread to multiple areas, doctors might use systemic treatments such as chemotherapy or immunotherapy. There is no single “best” treatment for all patients with MALT lymphoma because every case is different.^[1][9]

Medical societies and cancer organizations have established guidelines to help doctors choose the most appropriate treatment. These guidelines are based on years of research and clinical experience. However, because MALT lymphoma is relatively uncommon compared to other cancers, many treatment recommendations are based on smaller studies rather than large clinical trials. Researchers continue to explore new therapies, including drugs that target specific molecules involved in the growth of lymphoma cells. Some of these experimental treatments are being tested in clinical trials and may offer new hope for patients who don’t respond to standard therapies.^[1][9]

Standard Treatment Approaches

Standard treatment for MALT lymphoma varies depending on the location of the disease and whether it is linked to an infection or autoimmune condition. The approach is tailored to each patient’s specific situation, and several treatment options have been approved and used successfully for many years.

Treating Infection-Related MALT Lymphoma

Many cases of gastric MALT lymphoma are caused by chronic infection with a bacterium called Helicobacter pylori (H. pylori). When this bacterium is found in a patient’s stomach, the first line of treatment is to eradicate the infection using antibiotics. This approach is remarkably effective. Doctors typically prescribe a combination of antibiotics along with medications called proton pump inhibitors (PPIs), which reduce stomach acid and help the antibiotics work better. The treatment usually lasts about two weeks.^[4][10]

In about 90 percent of cases, treating the H. pylori infection causes the lymphoma to go away completely. This process is not instant—it can take several months for the lymphoma to disappear after the infection is cleared. Patients are monitored with follow-up tests to make sure the lymphoma is responding. If the lymphoma does not go away or comes back after antibiotic treatment, other treatments are available.^[11][23]

Other infections are also linked to MALT lymphoma in different parts of the body. For example, MALT lymphoma affecting the tissues around the eye (ocular adnexa) has been associated with infection by bacteria called Chlamydophila psittaci. In these cases, antibiotic therapy with doxycycline may be effective. Similarly, MALT lymphoma in some patients is linked to hepatitis C virus infection, and treating the viral infection with antiviral drugs can sometimes lead to improvement or remission of the lymphoma.^[4][11][14]

Watchful Waiting

Because MALT lymphoma grows slowly and may not cause symptoms for a long time, doctors sometimes recommend an approach called watchful waiting or active surveillance. This means that instead of starting treatment right away, the healthcare team carefully monitors the patient with regular checkups, blood tests, and imaging studies. Treatment is only started if symptoms develop or if there are signs that the disease is getting worse.^[4][10]

Watchful waiting is most appropriate for patients with early-stage disease who are not experiencing pain, weight loss, or other problems related to the lymphoma. This approach avoids the side effects of treatment and allows patients to maintain their quality of life. Regular monitoring ensures that if the disease does progress, it can be caught early and treated promptly.^[11][23]

Radiation Therapy

Radiation therapy uses high-energy rays to destroy cancer cells. For MALT lymphoma that is localized to one area of the body, radiation therapy can be highly effective. This treatment is often used for MALT lymphoma in the stomach, lungs, or ocular adnexa when the disease has not spread to other parts of the body.^[4][10]

In one study of 95 patients with MALT lymphoma of the ocular adnexa, nearly all patients treated with external beam radiation (doses ranging from 30.6 to 45.0 Gy) achieved a complete response, meaning the lymphoma could no longer be detected. The 3-year overall survival rate was 100 percent, and the event-free survival rate was 97 percent. Importantly, there were no serious complications from the radiation treatment.^[6][13]

Radiation therapy is typically given over several weeks, with treatments delivered five days a week. The exact duration and dose depend on the size and location of the lymphoma. Side effects can include fatigue, skin changes in the treated area, and temporary inflammation of nearby tissues. Most side effects are mild and go away after treatment is finished.^[6][13]

Targeted Therapy with Rituximab

Rituximab is a type of drug called a monoclonal antibody that targets a protein called CD20 found on the surface of B cells, including lymphoma cells. By attaching to CD20, rituximab marks the cancer cells for destruction by the immune system. Rituximab can be used alone or in combination with chemotherapy to treat MALT lymphoma.^[4][10]

Rituximab is given by intravenous infusion, typically once a week for several weeks. It has become a standard part of treatment for many patients with MALT lymphoma, especially when the disease has spread to multiple areas or when other treatments have not worked. Side effects can include fever, chills, and allergic reactions during the infusion, but these are usually manageable. Long-term side effects are less common but can include increased risk of infections.^[10][17]

Chemotherapy

Chemotherapy uses drugs to kill cancer cells throughout the body. For MALT lymphoma, chemotherapy is usually reserved for patients with more advanced disease that has spread to multiple sites or for those who have not responded to other treatments. Chemotherapy can be given alone or in combination with rituximab.^[4][10]

Common chemotherapy regimens for MALT lymphoma include bendamustine plus rituximab and R-CHOP, which stands for rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. These combinations are also used to treat other types of slow-growing lymphomas like follicular lymphoma. The choice of regimen depends on the patient’s overall health, age, and the characteristics of the lymphoma.^[11][23]

Chemotherapy is typically given in cycles, with each cycle lasting several weeks. Side effects vary depending on the drugs used but can include nausea, hair loss, fatigue, low blood counts, and increased risk of infections. Most side effects are temporary and improve after treatment is completed. Doctors monitor patients closely during chemotherapy and can adjust the treatment plan if side effects become too severe.^[11][23]

Surgery

Surgery is not commonly used as a primary treatment for MALT lymphoma, but it may be an option in certain situations. For example, if MALT lymphoma is found in the lung or breast and is confined to a small area, surgical removal of the affected tissue may be performed. Surgery may also be used if the lymphoma is causing complications, such as bleeding or obstruction.^[11][23]

In general, surgery is considered a local treatment and is not effective for lymphoma that has spread to multiple areas. It is most useful when the disease is very localized and can be completely removed. After surgery, patients may receive additional treatments such as radiation or chemotherapy to reduce the risk of the lymphoma coming back.^[11][23]

Treatment in Clinical Trials: Exploring New Options

Clinical trials are research studies that test new treatments to see if they are safe and effective. For patients with MALT lymphoma, especially those whose disease has come back after standard treatment or has not responded to existing therapies, clinical trials offer access to promising new drugs and approaches. These trials are carefully designed to answer specific questions about how well a new treatment works and what side effects it may cause.

Understanding Clinical Trial Phases

Clinical trials are conducted in phases, each with a specific purpose. Phase I trials test a new drug in a small group of people to evaluate its safety, determine a safe dosage range, and identify side effects. These trials are often the first time a drug is tested in humans. Phase II trials involve more participants and focus on whether the drug is effective against a particular disease and how well it is tolerated. Phase III trials compare the new treatment to the current standard treatment in a large group of patients to see if the new approach is better, the same, or worse. Phase III trials provide the evidence needed for regulatory approval of new drugs.^[9]

For MALT lymphoma, many clinical trials are in Phase II or Phase III, testing drugs that target specific molecules involved in the growth and survival of lymphoma cells. Because MALT lymphoma is relatively rare, large Phase III trials are less common than for more frequent cancers. However, research is ongoing, and new findings continue to improve treatment options.^[9]

Targeting B-Cell Receptor Signaling

Scientists have learned that MALT lymphoma cells depend on signals from the B-cell receptor pathway to grow and survive. This pathway involves a series of proteins that transmit signals from the surface of the cell to its interior, telling the cell to multiply and stay alive. By blocking this pathway with targeted drugs, it may be possible to stop the growth of lymphoma cells without harming normal cells as much as traditional chemotherapy does.^[9][14]

One key protein in this pathway is Bruton’s tyrosine kinase (BTK). When BTK is active, it sends signals that promote the survival and growth of B cells. Drugs that block BTK are called BTK inhibitors, and they have shown promise in treating several types of B-cell lymphomas, including MALT lymphoma.^[9][19]

Ibrutinib: A BTK Inhibitor

Ibrutinib is a BTK inhibitor that has been studied in patients with relapsed or refractory marginal zone lymphoma. In clinical trials, ibrutinib has shown significant activity against MALT lymphoma, leading to tumor shrinkage and symptom improvement in many patients. The drug is taken orally as a pill, which is more convenient than intravenous chemotherapy.^[9][19]

Ibrutinib works by blocking the BTK enzyme, which interrupts the signaling pathway that lymphoma cells need to survive. This causes the cancer cells to die or stop growing. Because ibrutinib targets a specific molecule, it tends to have different side effects than traditional chemotherapy. Common side effects include diarrhea, fatigue, bruising, bleeding, and irregular heart rhythms. Some patients also experience infections because the drug affects normal immune cells as well.^[9][19]

Clinical trial results have shown that ibrutinib can be effective in patients whose MALT lymphoma has relapsed after other treatments. The drug has been tested in Phase II and Phase III trials, and it has received regulatory approval for use in certain types of B-cell lymphomas. Research is ongoing to determine whether ibrutinib could be used as a first-line treatment for MALT lymphoma, either alone or in combination with other drugs such as rituximab.^[9][19]

Other Targeted Therapies Under Investigation

In addition to BTK inhibitors, researchers are studying other drugs that target different parts of the B-cell receptor signaling pathway. These include inhibitors of phosphoinositide 3-kinase (PI3K), another enzyme involved in cell growth and survival. PI3K inhibitors work similarly to BTK inhibitors by blocking signals that tell lymphoma cells to multiply.^[9][14]

Some clinical trials are also exploring the use of drugs that target the nuclear factor kappa B (NF-κB) pathway. This pathway is often overactive in MALT lymphoma cells and helps them survive even when they should die. By blocking NF-κB signaling, researchers hope to make lymphoma cells more vulnerable to treatment.^[14]

Another area of research involves studying the genetic changes that occur in MALT lymphoma cells. Certain genetic abnormalities, such as the t(11;18) translocation, are found in some MALT lymphomas and may predict how the disease will respond to treatment. Understanding these genetic changes could help doctors choose the best therapy for each patient and develop new drugs that target specific genetic abnormalities.^[1][14]

Immunotherapy Approaches

Immunotherapy is a type of treatment that helps the body’s immune system recognize and attack cancer cells. One form of immunotherapy being studied for MALT lymphoma is checkpoint inhibitors, which block proteins that prevent immune cells from attacking cancer. By blocking these checkpoints, the immune system is unleashed to fight the lymphoma more effectively.^[9]

Another immunotherapy approach involves CAR T-cell therapy, in which a patient’s own immune cells are collected, genetically modified to recognize lymphoma cells, and then returned to the patient’s body. CAR T-cell therapy has shown remarkable success in some types of aggressive lymphomas, and researchers are exploring whether it could also be used for indolent lymphomas like MALT lymphoma.^[9]

Where Clinical Trials Are Being Conducted

Clinical trials for MALT lymphoma are being conducted at cancer centers and research institutions around the world, including in the United States, Europe, and other regions. Patients interested in participating in a clinical trial should talk to their doctor, who can help them find trials that are appropriate for their situation. Eligibility for clinical trials depends on factors such as the stage of the lymphoma, previous treatments, and overall health.^[9]

Many clinical trials are designed to test new drugs in patients whose lymphoma has relapsed after initial treatment or has not responded to standard therapies. These trials offer access to cutting-edge treatments that are not yet widely available. Participation in a clinical trial also contributes to medical research and may help future patients with MALT lymphoma.^[9]

Most common treatment methods

• Antibiotic therapy
  • Used to treat Helicobacter pylori infection in gastric MALT lymphoma, typically combined with proton pump inhibitors for about two weeks.
  • Leads to complete remission in approximately 90 percent of gastric MALT lymphoma cases, though it may take several months.
  • Doxycycline has been used for ocular adnexal MALT lymphoma associated with Chlamydophila psittaci infection.
• Watchful waiting (active surveillance)
  • Monitoring approach where treatment is deferred until symptoms appear or disease progresses.
  • Regular checkups include blood tests, imaging studies, and physical examinations to track disease status.
  • Appropriate for patients with early-stage, slow-growing disease without symptoms.
• Radiation therapy
  • External beam radiation typically delivered at doses ranging from 30.6 to 45.0 Gy over several weeks.
  • Highly effective for localized MALT lymphoma in stomach, lungs, or ocular adnexa.
  • In one study of ocular adnexa MALT lymphoma, achieved 100% 3-year overall survival and 97% event-free survival with minimal complications.
• Targeted therapy
  • Rituximab, a monoclonal antibody targeting CD20 protein on B cells, can be used alone or with chemotherapy.
  • Given by intravenous infusion, typically once weekly for several weeks.
  • BTK inhibitors like ibrutinib block specific enzymes in the B-cell receptor signaling pathway, showing promise in relapsed/refractory MALT lymphoma.
• Chemotherapy
  • Reserved for advanced disease or patients who haven’t responded to other treatments.
  • Common regimens include bendamustine plus rituximab and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone).
  • Given in cycles over several weeks or months, with side effects including nausea, fatigue, hair loss, and low blood counts.
• Surgery
  • Used in selected cases for localized MALT lymphoma in lung or breast.
  • May be performed to remove isolated disease or address complications like bleeding or obstruction.
  • Often followed by additional treatments such as radiation or chemotherapy.
• Antiviral therapy
  • Used to treat hepatitis C virus infection in patients with HCV-associated MALT lymphoma.
  • Clearing the viral infection can sometimes lead to lymphoma remission.